

PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

QLOSI
(pilocarpine hydrochloride ophthalmic solution)

VUITY
(pilocarpine hydrochloride ophthalmic solution)

Status: CVS Caremark® Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Qlosi

Qlosi is indicated for the treatment of presbyopia in adults.

Vuity

Vuity is indicated for the treatment of presbyopia in adults.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of presbyopia in an adult patient

AND

- The patient has NOT been receiving the requested drug for at least 14 days

AND

- The presbyopia impacts the patient's activities of daily living to the point where pharmacologic intervention is required. [Documentation is required for approval.]

OR

- The patient has been receiving the requested drug for at least 14 days

AND

- The patient has demonstrated improvement from baseline presbyopia including gaining 3 lines or more in binocular distance corrected near visual acuity, without losing more than 1 line of corrected distance visual acuity. [Documentation is required for approval]

Quantity Limits apply.

QUANTITY LIMIT

Drug	1 Month Limit	3 Month Limit***
Qlosi 0.4% Ophthalmic Solution (pilocarpine hydrochloride ophthalmic solution)	60 single-patient use vials (12 pouches) / 25 days*	180 single-patient use vials (36 pouches) / 75 days*
Vuity 1.25% Ophthalmic Solution (pilocarpine hydrochloride ophthalmic solution)	5 mL / 19 days**	15 mL / 57 days**

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

**The duration of 19 days is used for a 25-day fill period and 57 days is used for a 75-day fill period to allow time for refill processing.

***For new starts, the mail limit will be the same as the retail limit. **The intent is for prescriptions of the requested drug to be filled one fill at a time for new starts, even if filled at mail order; there should be no 3-month supplies filled for new starts.**

Qlosi, Vuity PA with Limit Policy UDR 11-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

Duration of Approval (DOA):

- 5054-C: Initial therapy DOA: 2 months; Continuation of therapy DOA: 12 months

REFERENCES

1. Qlosi [package insert]. Ponte Vedra, FL: Orasis Pharmaceuticals, Ltd.; October 2023.
2. Vuity [package insert]. North Chicago, IL: AbbVie Inc.; March 2023.
3. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed August 4, 2023.
4. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/04/2023).
5. Jacobs DS, Afshari NA, Bishop RJ, et al. Refractive Errors Preferred Practice Pattern. *Ophthalmology*. 2023;130(3): P1-P60.
6. Pharmacy Auditing and Dispensing Job Aid: Billing Other Dosage Forms. Centers for Medicare and Medicaid Services. December 2015.
7. Waring GO 4th, Price FW Jr, Wirta D, et al. Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. *JAMA Ophthalmology*. 2022;140(4):363-371.
8. Clinicaltrials.gov. Allergan. Phase 3 Efficacy Study of AGN-190584 in Participants with Presbyopia (GEMINI 2). Last Updated December 2022. Retrieved from: <https://clinicaltrials.gov/ct2/show/NCT03857542?term=NCT03857542>. Accessed September 5, 2023.
9. Clinicaltrials.gov. Allergan. Study to Assess Safety and Efficacy in Participants Age 40 to 55 with Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo). Last Updated: March 2023. Retrieved from: <https://class.clinicaltrials.gov/ct2/show/NCT04983589>. Accessed September 05, 2023.
10. Jacobs DS, Lee JK, Shen TT, et al. Refractive Surgery Preferred Practice Pattern. *Ophthalmology*. 2023;130(3): P61-P135.